A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met,
suggesting that its anti-tumor effect mainly inhibits the activation of key downstream
oncogenic pathways by inhibiting expression of c-met, tumor angiogenesis and tumor cell
migration.